Ionis' TRYNGOLZA Approved by FDA for Severe Hypertriglyceridemia

Ionis Pharmaceuticals announced that the U.S. FDA has approved TRYNGOLZA (olezarsen) as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (sHTG). The approval was based on positive Phase 3 CORE and CORE2 studies, which demonstrated up to 72% reduction in fasting triglyceride levels and up to 91% reduction in acute pancreatitis events. TRYNGOLZA, which is Ionis' first independent commercial launch in a prevalent condition, will be available in the U.S. in July.